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Abstract
Visceral leishmaniasis (VL), a zoonotic disease caused by Leishmania infantum, is endemic in Algeria. This report describes a
retrospective epidemiological study conducted on human VL to document the epidemiological profile at national level. All
human VL cases notified by the National Institute of Public Health between 1998 and 2008 were investigated. In parallel all
VL cases admitted to the university hospitals of Algiers were surveyed to estimate the underreporting ratio. Fifteen hundred
and sixty-two human VL cases were reported in Algeria between 1998–2008 with an average annual reported incidence rate
of 0.45 cases per 100,000 inhabitants, of which 81.42% were in the age range of 0–4 years. Cases were detected year-round,
with a peak notification in May and June. One hundred and seventy patients were admitted to the university hospitals in
Algiers in the same period, of which less than one in ten had been officially notified. Splenomegaly, fever, pallor and
pancytopenia were the main clinical and laboratory features. Meglumine antimoniate was the first-line therapy for
paediatric VL whereas the conventional amphotericin B was used for adult patients. Visceral leishmaniasis in Algeria shows
the epidemiological profile of a paediatric disease with a decrease of the annual reported incidence rate. However, vigilance
is required because of huge underreporting and an apparent propagation towards the south.
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Introduction
Visceral leishmaniasis (VL), a vector-born parasitic disease
causing febrile splenomegaly, pancytopenia and wasting, has been
reported in Algeria since the beginning of the 20th century [1]. In
the Mediterranean basin, VL is caused by Leishmania infantum and it
is a zoonotic disease with dogs considered to be the main reservoir
of the parasite [2,3]. In Algeria, the sand fly vectors are Phlebotomus
perniciosus and P. longicuspis [4,5]. The geographical distribution of
VL covers all the humid and sub-humid regions in the north of the
country [6]. The disease affects mainly children under 5 years of
age, most of them belonging to poor families residing in rural areas
[7–9].
Leishmaniasis is a re-emerging disease in Algeria and seems to
spread because of a combination of factors: environmental
changes as well as factors related to the immune status of the
host and drug resistance [10,11]. Several epidemiological surveys
on VL have been conducted between 1972 and 1990 in the main
Algerian hospitals [7,8,12]. The most recent national report
mentions 1121 cases over a six-year period (1985–1990) contrast-
ing with 721 cases reported during the previous 9 years (1975–
1984). It showed an extension of VL from the old foci in Kabylie
(Tizi-Ouzou, Bejaı¨a) to the centre (Blida, Chlef, Medea, Tipaza)
and the north-eastern part of northern Algeria, with scattered
cases occurring in the West (Oran, Tlemcen, Figure 1). The
average annual incidence rate doubled over those periods reaching
0.73 per 100,000 inhabitants per year by 1990. Notification of VL
is compulsory in Algeria since 1990. Globally, the World Health
Organisation considers that under-reporting is substantial [13],
although specifically for Algeria, it was recently estimated as mild
(1.2–1.8 fold) [14]. The main objective of the present study is to
portray the epidemiological profile of VL in Algeria between 1998
and 2008.
Materials and Methods
Algeria is the largest country of Africa and it consists of four
ecological zones of unequal size. The northern Tell region has a
Mediterranean climate, characterised by warm, dry summers and
cool, wet winters. The total annual rainfall ranges from 400 to
1000 mm. Natural forests are concentrated in a 100–200 km wide
belt in the north of the country [15]. The north-western part of the
country is more arid (rainfall 200–400 mm). The climate becomes
progressively drier when moving south. The Sahara desert is an
arid, windy area with large daily temperature differences and a
total annual rainfall below 130 mm. Lastly, the Hoggar Massif
(7% of the country) lies south of the Sahara. It is a succession of
high altitude desert areas, rising in terraces to an altitude of
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2900 m. Administratively, Algeria is divided into 48 provinces. In
2008, 66% of the Algerian population lived in urban areas
(National Bureau of Statistics, 2010).
Data Collection
We compiled all the data on official case notifications of VL in
Algeria between 1998 and 2008. Our main data source was the
epidemiological surveillance database of the National Institute of
Public Health (INSP). The INSP data are the result of passive
monitoring, based on the notifications registered by the epidemi-
ological services of all health sectors of the entire Algerian territory
(local public health facilities, public hospitals, university hospitals).
Private physicians are held to notify the VL cases to the
epidemiological service to which they are attached. This database
contains anonymous patient data including gender, age, residence
and time of hospitalisation of VL patients. To estimate the degree
of underreporting, we carried out a survey in 5 university hospitals
(UH) of Algiers, the capital city. It should be noted that the UH of
Algiers receive patients from all over the country.
A standard form was used to extract epidemiological data from
the patient files of all those admitted with a VL final diagnosis to
the departments of pediatrics, internal medicine and infectious
diseases between January 1998 to March 2009. The two data
sources were linked on the basis of date of admission/notification,
residence, sex and age.
Data Analysis
Stata/MP 12.1 [16] was used for the statistical analysis. We
computed standardised incidence ratios (SIR) to allow compari-
sons between provinces taking the national average incidence rate
as a reference. The chi-squared test for trend (Mantel-Haenszel)
was used to assess time-evolution of VL. A linear correlation
analysis of incidence rate and urban population rate (Ministry of
Housing and Urban Development, 2010) was performed. The
human VL incidence and the urban population rate were plotted
on a map with Arcview 3.2 (ESRI, Redlands, California). We used
the website http://www.gadm.org/countryres to download the
administrative regions of Algeria and we obtained the georefer-
enced data on the cities of Algeria from http://dateandtime.info.
Ethical Aspects
Clearance for the study was obtained from the Ministry of
Health (Direction of prevention) of Algeria and from the hospitals
included in the study. Ethical clearance was obtained from the
Institutional Review Board of the Institute of Tropical Medicine,
Antwerp. All data handled in this study were treated with due
respect for confidentiality and fully and untraceably anonymised
by the first author (AA). For the hospital survey the data was
extracted from the patient records by the clinician in charge onto
an individual questionnaire format, without copying any personal
identifiers that would allow identification of individual patients.
The main investigator of this study (AA) collected the question-
naires from the clinicians and entered the data in a single
database.
Results
One thousand five hundred and sixty-two (1562) VL cases were
reported between 1998 and 2008 from the 48 provinces of Algeria
to the INSP (Table 1). The average number of cases in Algeria was
142 cases per year and the average annual incidence rate was 0.45
VL cases per 100,000 inhabitants. One thousand two hundred fifty
eight VL cases were between 0–4 years old (81.42%) with an
Figure 1. Algeria: localities referred to in the text.
doi:10.1371/journal.pone.0099207.g001
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Table 1. Provinces of Algeria with the corresponding number of cases and percentage of cases between 1998 and 2008.
Province 98 99 00 01 02 03 04 05 06 07 08 Tot. Perc.{
Adrar 1 0 0 2 1 0 0 0 0 1 0 5 0.32
Ain defla 7 4 6 1 2 0 3 3 3 1 0 30 1.92
Ain temouchent 3 1 0 0 0 0 1 0 0 2 0 7 0.45
Alger 3 0 1 0 4 0 1 1 4 4 0 18 1.15
Annaba 0 2 4 2 1 0 0 0 1 0 0 10 0.64
Batna 8 3 6 3 3 7 9 8 2 1 1 51 3.27
Bechar 0 1 0 0 0 0 0 0 0 0 0 1 0.06
Bejaia 60 15 39 13 2 11 11 13 6 4 9 183 11.72
Biskra 14 12 11 14 19 15 5 2 10 9 4 115 7.36
Blida 4 0 2 2 0 4 3 3 3 0 0 21 1.34
Bordj bouarreridj 13 1 8 8 4 3 5 5 3 8 0 50 3.2
Bouira 18 7 24 1 1 5 7 10 1 10 6 90 5.76
Boumerdes 5 4 4 3 0 0 7 7 0 0 1 31 1.98
Chlef 0 2 2 1 2 1 0 1 2 3 2 16 1.02
Constantine 1 3 3 1 2 9 5 3 5 2 0 34 2.18
Djelfa 0 0 0 0 0 0 0 0 0 0 0 0 0
El bayadh 0 0 0 0 0 0 0 0 0 0 0 0 0
El oued 0 0 0 0 3 3 0 0 1 2 1 10 0.64
El tarf 0 1 0 1 0 1 0 0 0 0 0 3 0.19
Ghardaia 0 0 6 0 0 8 0 1 0 0 0 15 0.96
Guelma 4 0 5 1 2 0 3 2 2 3 2 24 1.54
Illizi 0 0 0 2 1 0 5 2 1 1 0 12 0.77
Jijel 6 2 6 6 0 0 2 1 2 2 5 32 2.05
Khenchela 1 2 0 0 0 1 1 0 0 0 2 7 0.45
Laghouat 0 0 0 0 0 0 0 0 2 0 0 2 0.13
Mascara 0 0 0 0 0 0 0 0 0 1 0 1 0.06
Medea 11 5 10 6 6 4 4 7 4 4 3 64 4.1
Mila 51 32 30 30 17 21 21 11 14 3 9 239 15.3
Mostaganem 1 0 3 2 1 1 0 0 0 0 0 8 0.51
Msila 3 3 5 1 2 0 1 0 1 0 1 17 1.09
Naama 0 0 0 0 0 0 0 1 1 0 0 2 0.13
Oran 7 5 0 6 7 9 3 1 0 1 0 39 2.5
Ouargla 0 0 0 0 0 0 4 1 1 1 0 7 0.45
Oum el bouaghi 0 3 1 3 4 1 0 1 1 6 2 22 1.41
Relizane 1 0 0 0 0 0 1 0 0 2 5 9 0.58
Saida 0 1 0 0 0 0 1 0 1 0 0 3 0.19
Setif 33 19 21 8 8 9 9 12 9 6 13 147 9.41
Sidi bel abbes 0 0 0 0 0 0 0 1 0 1 0 2 0.13
Skikda 2 2 1 0 4 1 1 3 1 0 2 14 0.9
Souk ahras 0 0 3 0 0 2 2 6 3 7 2 25 1.6
Tamanrasset 5 3 1 2 1 0 0 0 1 1 2 16 1.02
Tebessa 1 0 0 0 0 1 1 1 3 3 2 12 0.77
Tiaret 1 0 0 0 2 0 1 0 1 0 1 6 0.38
Tindouf 0 0 0 0 0 0 0 0 0 0 0 0 0
Tipaza 5 2 5 1 2 0 3 1 2 3 2 26 1.66
Tissemsilt 1 1 1 1 0 5 3 0 0 7 3 22 1.41
Tizi ouzou 38 14 20 6 4 8 7 4 0 5 0 106 6.79
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average annual incidence rate of 3.32 cases per 100.000
inhabitants in this group. The male: female ratio was 1.24.
One thousand two hundred seventy four of the VL cases
(81.56%) came from provinces located in the central and eastern
parts of northern Algeria. Mila (239), Bejaia (183), Setif (147),
Biskra (115) and Tizi-Ouzou (106) reported the highest number of
cases. Table 2 reports the average VL annual incidence rates per
100,000 inhabitants by province with the corresponding SIR.
Mila, Bejaia, Illizi, Biskra, Bouira, Tizi-Ouzou and Setif appeared
to be above the national average annual incidence rate (Figure 2).
The Pearson correlation coefficient between the incidence rate
and the urban population rate was 20.34 with a p value of 0.0176
(Figure 3 and Figure 4). In addition to the rural environment, the
presence of VL cases could be linked to the proximity of natural
parks (Tizi-ouzou and Bouira with Djurdjura park, Bejaia with
Gouraya park, Blida with Chrea park, Mila with Taza national
park and Illizi with Tassili NAjjer park).
Table 1. Cont.
Province 98 99 00 01 02 03 04 05 06 07 08 Tot. Perc.{
Tlemcen 0 1 0 0 1 1 0 0 2 0 0 5 0.32
Total 308 151 220 127 106 131 130 112 93 104 80 1562
Tot. = total; Perc. = percentage.
{percentage of cases reported between 1998 and 2008.
doi:10.1371/journal.pone.0099207.t001
Figure 2. Human visceral leishmaniasis cases in Algeria (percentage of total cases) (1998–2008; N=1562).
doi:10.1371/journal.pone.0099207.g002
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Table 2. The average visceral leishmaniasis annual incidence rates per 100,000 inhabitants by province with the corresponding
Standardised Incidence Rate (SIR).
Wilaya Incidence{ SIR IC 95%
Adrar 0.14 0.03 [0.00; 0.05]
Ain defla 0.39 0.95 [0.61; 1.29]
Ain temouchent 0.18 0.39 [0.10; 0.68]
Alger 0.06 0.16 [0.03; 0.29]
Annaba 0.15 0.47 [0.18; 0.76]
Batna 0.45 1.06 [0.77; 1.35]
Bechar 0.04 0.09 [–0.09; 0.28]
Bejaia 1.8 5.33 [4.56; 6.10]
Biskra 1.7 3.54 [2.90; 4.19]
Blida 0.22 0.62 [0.35; 0.88]
Bordj bouarreridj 0.77 1.77 [1.28; 2.26]
Bouira 1.21 3.1 [2.46; 3.75]
Boumerdes 0.4 0.99 [0.64; 1.33]
Chlef 0.16 0.39 [0.20; 0.59]
Constantine 0.35 1.01 [0.67; 1.34]
Djelfa 0 0
El bayadh 0 0
El oued 0.17 0.33 [0.12; 0.53]
El tarf 0.07 0.21 [–0.03; 0.44]
Ghardaia 0.43 0.92 [0.45; 1.38]
Guelma 0.47 1.29 [0.78; 1.81]
Illizi 3.02 3.72 [1.62; 5.83]
Jijel 0.47 1.19 [0.78; 1.60]
Khenchela 0.18 0.43 [0.11; 0.75]
Laghouat 0.05 0.12 [–0.05; 0.28]
Mascara 0.01 0.03 [–0.03; 0.10]
Medea 0.69 1.72 [1.30; 2.15]
Mila 3 7.24 [6.32; 8.15]
Mostaganem 0.11 0.28 [0.09; 0.48]
Msila 0.18 0.39 [0.21; 0.58]
Naama 0.13 0.33 [–0.13; 0.79]
Oran 0.27 0.78 [0.53; 1.02]
Ouargla 0.14 0.27 [0.07; 0.47]
Oum el bouaghi 0.36 0.89 [0.52; 1.27]
Relizane 0.12 0.3 [0.11; 0.50]
Saida 0.09 0.16 [–0.02; 0.35]
Setif 0.95 2.34 [1.97; 2.72]
Sidi bel abbes 0.03 0.05 [–0.02; 0.11]
Skikda 0.15 0.49 [0.23; 0.74]
Souk ahras 0.57 1.56 [0.95; 2.17]
Tamanrasset 0.98 1.85 [0.94; 2.75]
Tebessa 0.19 0.4 [0.17; 0.63]
Tiaret 0.07 0.17 [0.03; 0.30]
Tindouf 0 0
Tipaza 0.43 1.2 [0.74; 1.66]
Tissemsilt 0.71 1.65 [0.96; 2.33]
Tizi ouzou 0.8 2.63 [2.13; 3.14]
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The highest number of cases was reported in 1998 (308)
(Figure 5). For the period 1998–2008, a clear trend towards
reduction in the annual number of VL cases over time (years) was
observed (Chi2 = 245.156, df = 10, pv0.001). The monthly
distribution of cases based on the admission date, is shown in
Figure 6. Cases were reported in all months, with a minimum in
December (56 cases) and a maximum in May and June (176 cases).
The main cluster of cases was observed in the March–July period
(850/1560 cases, 54.45%).
During our survey at the five university hospitals of Algiers we
recorded 170 patients. Thirty three provinces of Algeria were
represented and the majority originated from the central part of
northern Algeria (124, 72.94%). Cross-checking of the data
showed that only 8.24% (14/170) of the cases where notified in
the INSP database.
At admission, 56.6% of the patients reported the onset of
symptoms in the previous two months, and for 41.51% of them
onset did not precede 30 days. Nevertheless, in 30.19% of the
cases, this value was higher than 3 months. Table 3 shows the time
between symptom onset and admission. The main clinical and
laboratory features of VL in Algeria are summarized in Figure 7.
The most frequent findings were splenomegaly (95.04%), fever
(88.89%), pallor (88.89%), and pancytopenia (69.23%). First-line
VL diagnosis was based on a direct microscopic visualisation of
Leishmania amastigotes in bone marrow aspirates (94%) and in
54.43% of cases the immunofluorescence antibody test (IFAT) was
carried out. The Western-Blot technique was used for 4 patients
(2.35%). Meglumine antimoniate was the first-line therapy for
94.95% of the pæ diatric VL cases. Unresponsive patients were
treated with miltefosine or liposomal amphotericin B. Conven-
tional amphotericin B was the first-line regimen for adult patients.
Nine percent of patients did not respond or died during treatment.
Table 2. Cont.
Wilaya Incidence{ SIR IC 95%
Tlemcen 0.05 0.14 [0.02; 0.27]
Total 0.45
{average annual incidence rate of visceral leishmaniasis per 100,000 inhabitants per region.
doi:10.1371/journal.pone.0099207.t002
Figure 3. Distribution of human visceral leishmaniasis in North of Algeria, in function of the % of urban population (1998–2008;
N=1562).
doi:10.1371/journal.pone.0099207.g003
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Discussion
In the study period (1998–2008) the reported annual incidence
rate of VL in Algeria decreased below 0.5 per 100,000 inhabitants.
This annual incidence is comparable to what is observed in
southern European countries endemic for VL [17]. This rate is
however, lower than in Tunisia (1.04 per 100,000 inhabitants)
(Aoun et al., 2009) and Turkey (1.6–8.53 per 100,000 inhabitants)
[17]. Such incidence data should be handled with caution, as they
depend much on the degree of underreporting which may be
variable across countries. In our study, less than 1 in 10 cases
observed in the Algiers university hospitals was actually notified to
the national epidemiological surveillance centre that is the source
for the official data: this tenfold under-reporting stands in sharp
contrast with the mild under-reporting, referred to in [14].
Noteworthy, a relatively higher number of VL cases was observed
from 1995 till 2000 (Figure 5) probably because of the political
instability during the nineties that did not allow the implemen-
tation of vector control programs. The sex ratio (male:female)
equals 1.24 and this is lower than that reported by [18]. It is
however difficult to comment on this difference, given the small
Figure 4. Distribution of human visceral leishmaniasis in South of Algeria, in function of the % of urban population (1998–2008;
N=1562).
doi:10.1371/journal.pone.0099207.g004
Figure 5. Evolution of the annual incidence of visceral leishmaniasis in Algeria (1989–2008) (N=2631).
doi:10.1371/journal.pone.0099207.g005
Visceral Leishmaniasis in Algeria
PLOS ONE | www.plosone.org 7 June 2014 | Volume 9 | Issue 6 | e99207
sample size of the latter study and the possibility that it is not
representative of the national population.
VL cases are observed year-round in Algeria. The fact that
54.45% of all cases were reported between March to July can be
explained because of the seasonal transmission of Leishmania
infantum from May to October [8], the long incubation period of
VL and the variability of individual susceptibility to the infection
[19]. This is in agreement with the findings by Aoun et al. 2009
[20] in Tunisia.
From 1998 to 2008, 45 provinces on the 48 reported at least one
case of visceral leishmaniasis. Djelfa, El Bayadh and Tindouf
appear to be free from the disease since 1998. Geographically, VL
remains a disease of the humid and sub-humid regions in the
North of Algeria [6]. The number of VL cases is equally
distributed over the east (40.97%) and the centre (40.59%) of
northern Algeria. 72.55% of the cases in the Central region
occurred in the region of la Grande-Kabylie. Nonetheless the
number of cases in Tizi-Ouzou, the biggest city of la Grande-
Kabylie, decreased from 285 cases (years 1985–1990) [8] to 106
cases (years 1998–2008). This drop can be explained by the
awareness of the local authorities that recognized there was a VL
outbreak and responded with enhanced vector control by
pyrethroid spraying (Deltamethrin).
In this region in addition to dogs, wild canids, such as jackals
(Canis aureus), could be potential feral reservoirs for L. infantum [21].
In fact, looking at the distribution of the jackal in Algeria [22], a
concordance can be observed with the distribution of VL cases. In
Bejaia, Tizi-Ouzou and Bouira, a close contact was noted between
dogs and jackals. In Tizi-Ouzou, the strain Leishmania infantum
Mon1 was isolated on a three years old jackal, captured during
2007 [23].
VL has spread southward as shown by the map (11.85% of the
cases); 115 cases were reported in Biskra during this period studied
versus 31 cases in the previous study from 1985 to 1990 [8].
Biskra, the gate to the great south, is rich of palm plantations. In
this city, the sewage water is collected in septic tanks which today
rises to the surface and pollutes the ground water. These man-
made environmental changes may increase human exposure to the
sandfly vector.
Moreover, cases were notified from the province of Illizi for the
first time. Furthermore, when comparing between-province
incidence rates, Biskra and Illizi, two provinces of the South,
were respectively the third and forth most infected towns.
The survey at the five University Hospitals (UH) of Algiers
documented 170 cases including one never notified pæ diatric case
from Djelfa in 2008. The 30 VL cases among residents of Algiers
were either persons living in the periurban areas, i.e. an
agricultural area with active transmission or persons who had
sojourned in other regions as Tizi-Ouzou, Bejaia or Setif. For 114
out of 170 patients the area of residence was recorded and socio-
economic status only for 40. Thus, 94/114 patients were from a
rural area (82.46%) and 33/40 (82.5%) had a very low social
socio-economic status and lived in poor housing conditions known
to be risk factors for VL [10,24,25].
VL remains mainly a paediatric disease in Algeria as in other
countries such as Tunisia [20], Morocco [25], Albania [26] and
Brazil [27]. Adult cases represent only 4.9% of the total number
reported. This proportion is similar to the one in Tunisia [20] but
it is different from the situation in some northern Mediterranean
countries that report larger proportions of adults affected (40–
Figure 6. Visceral leishmaniasis distribution per month (1998–2008) (N=1562).
doi:10.1371/journal.pone.0099207.g006
Table 3. Time between symptom onset and hospitalization
for visceral leishmaniasis suspicion in Algeria.
Period Percentage 95%CI
ƒ15 days 16.98 9.14–24.82
[15 30] days 24.53 15.10–33.96
[1 2] months 15.09 7.70–22.48
[2 3] months 13.21 6.29–20.13
[3 4] months 8.49 2.94–14.04
[4 6] months 8.49 2.94–14.04
[6 12] months 8.49 2.94–14.04
w12 months 4.72 0.58–8.86
doi:10.1371/journal.pone.0099207.t003
Visceral Leishmaniasis in Algeria
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70%) due to HIV-coinfection [28] and intravenous drug use.
Nevertheless, a clear decrease in the incidence of Leishmania-HIV
coinfection was observed by the end of the 1990s due to the
routine use of highly active antiretroviral therapy in AIDS patients
in most of southern Europe [29]. Thus, France reported from
1999 to 2012, 366 VL cases of which 31.4% were HIV infected,
9.6% had an immunosuppressive treatment and 3.3% had
received an organ or bone marrow transplant [30]. In Italy,
14% of total VL cases notified during a 30 years period were HIV
co-infected patients (1982–2012) whereas the other concomitant
conditions were organ transplantation, hepatitis and liver cirrhosis,
pregnancy, leukaemia, lymphoma, hepatitis B and systemic lupus
erythematosus and diabetes [31]. In Greece, 15% of the VL cases
were immunocompromised [32]. In our series 17 of the 25 adult
VL cases observed in the hospital survey were HIV-coinfected.
The eight remaining patients presented either medullary granu-
lomatosis, diabetes, hepatitis B with tuberculosis, systemic lupus
erythematosus (2 cases), leukaemia, vitamin B12 deficiency or a
flu-like syndrome.
The median time lag between symptom onset and the
hospitalization for suspicion of VL was in 56.6% of the cases
between 0 and 2 months of which 41.51% did not exceed 30 days.
These results are similar to the diagnostic delay observed in
Tunisia [20] and in Italy [33]. Nevertheless, in 30.19% of the
cases, diagnostic delay exceeded 3 months. This could be due to
misperception of the seriousness of early signs by the child’s
parents [34] or by doctors.
Until the early 1990s, pentavalent antimony was the only drug
employed for the treatment of VL in the Mediterranean, with
reported cure rates exceeding 95% in immunocompetent patients
[35]. While conventional amphotericin B (Fungizone) is the first-
line therapy for adult patients, meglumine antimoniate (Sb(v))
(Glucantime) till date remains the main treatment of paediatric VL
in Algeria [28] and is available free of charge at public hospitals.
Resistance to Sb(v) does not seem to be yet a major problem yet.
Unresponsive patients are treated with miltefosine or liposomal
amphotericin B (Ambisome) when available. The high cost of the
latter did not allow its use as a first-line drug as it is the case in
France since 1994, and in Italy and Cyprus [35,36]. Recently the
World Health Organization obtained a preferential pricing
scheme for liposomal amphotericin B of US$ 20.00 per vial, valid
for public sector agencies of developing countries for the treatment
of VL [37,38]. This scheme opens the prospect of inclusion of this
highly efficacious and safe drug in therapeutic regimens.
In conclusion, VL in Algeria shows the epidemiological profile
of a paediatric disease. A decrease of the annual incidence rate was
observed compared to the previous decade. However, vigilance is
required because of huge underreporting and an apparent
propagation towards the south. Immunocompromised adults
constitute another sub-population at risk. Further studies should
be carried out in the most affected cities with special consideration
for the spatial variability in disease occurrence.
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